2025 年 9 月 25 日- 下午 1:21
蒙特利尔，2025 年 9 月 25 日（GLOBE NEWSWIRE）——Theratechnologies Inc.（“ Theratechnologies” 或 “ 公司”）（TSX:TH）（NASDAQ:THTX），一家商业阶段的生物制药公司，今天宣布完成之前宣布的根据《商业公司法》（魁北克）第 XVI 章第 II 节涉及 CB Biotechnology, LLC（“ 买方”）的安排计划，买方为 Future Pak, LLC（“ Future Pak”）的关联公司，根据该计划，买方以每股 3.01 美元现金加每股一项附带价值权（“ CVR”）的形式收购了公司所有已发行和流通的普通股（“ 股份”），如果公司达到某些里程碑，买方将额外支付每个 CVR 最高 1.19 美元的现金（“ 安排”）。
股份的对价已由买方汇款至 Computershare Investor Services Inc.，作为安排下的保管人，并将在此日期后尽快支付给 Theratechnologies 的前股东（或在注册股东的情况下，在保管人收到正确填写并签署的转让信函及代表其曾持有股份的股票证书和/或 DRS 建议后尽快支付）。
每个 CVR 是一个合同权利，赋予持有人在公司达到某些里程碑时从买方获得最高 1.19 美元的总支付，具体按照今天买方、Future Pak 和 Computershare Trust Company of Canada 作为 CVR 代理人之间签订的协议进行。CVR 在 CVR 代理人保留的登记册中记录，并不通过证书或任何其他工具证明。根据独立第三方评估师准备的报告，公司和买方已确定每个 CVR 的公允市场价值为 2025 年 9 月 24 日的 0.80 美元。
由于安排的完成，预计股份将在 2025 年 9 月 26 日左右从多伦多证券交易所退市，并将在 2025 年 9 月 25 日左右从纳斯达克资本市场退市。公司将申请在加拿大所有省份停止作为报告发行人。公司还将根据《1934 年美国证券交易法》修订版注销股份。
提前警告报告
在安排的生效日期之前，买方及其关联公司未持有任何股份。提前警告报告将在 www.sedarplus.ca 的公司档案下提交至 SEDAR+。有关更多信息和/或提前警告报告的副本，请联系以下人员。买方的总部位于 CB Biotechnology, LLC c/o Honigman LLP, 2290 First National Building, 660 Woodward Avenue, Detroit, MI 48226-3506。
关于 Theratechnologies
Theratechnologies（TSX: TH）（NASDAQ: THTX）是一家专注于商业化创新疗法的专业生物制药公司，这些疗法有潜力重新定义护理标准。有关 Theratechnologies 的更多信息，请访问其网站 www.theratech.com。
关于 Future Pak
Future Pak 成立于 1977 年，总部位于密歇根州 Wixom，连同其关联公司，是一家私营合同制造商、包装商和药品及营养保健品的分销商。Future Pak 在零售、专业和机构市场运营，利用其强大的基础设施和合作伙伴网络提供以质量为先、以患者为中心的解决方案。
前瞻性信息
本新闻稿包含前瞻性声明和前瞻性信息（统称为 “ 前瞻性声明”），根据适用的证券法，这些声明基于我们管理层的信念和假设以及当前可用的信息。您可以通过 “可能”、“将”、“如果”、“应该”、“可以”、“有希望”、“会”、“展望”、“相信”、“计划”、“设想”、“预期”、“期待” 和 “估计” 等术语或这些术语的否定形式或变体来识别前瞻性声明。本新闻稿中包含的前瞻性声明包括但不限于关于股份从多伦多证券交易所和纳斯达克资本市场退市、公司在加拿大所有省份停止作为报告发行人的声明，以及根据修订版《1934 年美国证券交易法》注销股份的声明。
这些前瞻性声明表达了截至本新闻稿日期，公司对未来事件或结果的估计、预测、展望、期望或意见，以及公司认为在特定情况下适当的其他一般性和特定假设。尽管公司相信这些前瞻性声明所产生的期望是基于有效和合理的基础和假设，但这些前瞻性声明本质上受到重要风险和不确定性的影响，其中许多超出了公司的控制范围，因此实际结果可能与这些前瞻性声明中披露或暗示的结果有显著差异。重要的风险和不确定性包括但不限于，股票可能不会在当前预期的时间内从多伦多证券交易所或纳斯达克资本市场退市，股票可能根本不会退市，原因可能是未能及时或以其他方式满足退市所需的条件，或其他原因，公司申请根据适用的加拿大证券法停止作为报告发行人的申请可能不会被接受或可能会延迟，以及公司可能未能实现与 CVR 相关的任何里程碑。
读者需注意，以上因素列表并不详尽，不应对前瞻性声明过度依赖。因此，建议读者实际结果可能与预期结果有实质性差异。除非适用的证券法另有要求，公司明确声明不打算，也不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。
如需更多信息，请联系：
Future Pak
投资者和媒体可联系 media@futurepak.com。
<img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVek5UUTBNQ00zTVRZMU5UZzJJekl3T0RNek9ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVek5UUTBNQ00zTVRZMU5UZzJJekl3T0RNek9ETT0"/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjE5ZWExOGMtODBkOS00ZjgyLTg0MGUtZTU2MDBkOTNhMzM2LTEwOTQ5NTQtMjAyNS0wOS0yNS1lbg==/tiny/Theratechnologies.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjE5ZWExOGMtODBkOS00ZjgyLTg0MGUtZTU2MDBkOTNhMzM2LTEwOTQ5NTQtMjAyNS0wOS0yNS1lbg==/tiny/Theratechnologies.png"/>

THTX

Theratechnologies Inc. 已完成对 Future Pak 的收购，股东将获得每股 3.01 美元的现金，以及基于业绩里程碑的最高可达每股 1.19 美元的潜在额外支付。收购完成后，Theratechnologies 的股票将从多伦多证券交易所和纳斯达克退市，公司将不再是加拿大的报告发行人，并根据美国证券法注销注册。或有价值权利（CVRs）的公允市场价值已评估为 0.80 美元

09/25/2025 - 01:21 PM
<div class="lb-trans">2025 年 9 月 25 日- 下午 1:21
</div>MONTREAL, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“ Theratechnologies” or the“ Company”) (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, announced today the completion of the previously-announced plan of arrangement under ChapterXVI – DivisionII of the Business Corporations Act (Québec) involving CB Biotechnology, LLC (the “ Purchaser”), an affiliate of Future Pak, LLC (“ Future Pak”), pursuant to which the Purchaser has acquired all the issued and outstanding common shares of the Company (the&#34; Shares&#34;) for US$3.01 per Share in cash plus one contingent value right (“ CVR”) per Share for additional aggregate cash payments of up to US$1.19 per CVR if certain milestones are achieved by the Company (the&#34; Arrangement&#34;).
<div class="lb-trans">蒙特利尔，2025 年 9 月 25 日（GLOBE NEWSWIRE）——Theratechnologies Inc.（“ Theratechnologies” 或 “ 公司”）（TSX:TH）（NASDAQ:THTX），一家商业阶段的生物制药公司，今天宣布完成之前宣布的根据《商业公司法》（魁北克）第 XVI 章第 II 节涉及 CB Biotechnology, LLC（“ 买方”）的安排计划，买方为 Future Pak, LLC（“ Future Pak”）的关联公司，根据该计划，买方以每股 3.01 美元现金加每股一项附带价值权（“ CVR”）的形式收购了公司所有已发行和流通的普通股（“ 股份”），如果公司达到某些里程碑，买方将额外支付每个 CVR 最高 1.19 美元的现金（“ 安排”）。
</div>Consideration for the Shares has been remitted by the Purchaser to Computershare Investor Services Inc., as depositary under the Arrangement, and will be paid to former shareholders of Theratechnologies as soon as reasonably practicable after the date hereof (or, in the case of registered shareholders, as soon as reasonably practicable after a properly completed and signed letter of transmittal is received by the depositary together with the share certificate(s) and/or DRS Advice(s) representing Shares formerly held by them).
<div class="lb-trans">股份的对价已由买方汇款至 Computershare Investor Services Inc.，作为安排下的保管人，并将在此日期后尽快支付给 Theratechnologies 的前股东（或在注册股东的情况下，在保管人收到正确填写并签署的转让信函及代表其曾持有股份的股票证书和/或 DRS 建议后尽快支付）。
</div>Each CVR is a contractual right that entitles the holder thereof to aggregate payments from the Purchaser of up to US$1.19 per CVR if certain milestones are achieved by the Company, the whole in accordance with the agreement entered into on the day hereof among the Purchaser, Future Pak and Computershare Trust Company of Canada as CVR agent. The CVRs are recorded in a register kept by the CVR agent and are not evidenced by a certificate or any other instrument. Based on a report prepared by an independent third-party valuator, the Company and the Purchaser have determined the fair market value of each CVR to be US$0.80 as at September 24, 2025.
<div class="lb-trans">每个 CVR 是一个合同权利，赋予持有人在公司达到某些里程碑时从买方获得最高 1.19 美元的总支付，具体按照今天买方、Future Pak 和 Computershare Trust Company of Canada 作为 CVR 代理人之间签订的协议进行。CVR 在 CVR 代理人保留的登记册中记录，并不通过证书或任何其他工具证明。根据独立第三方评估师准备的报告，公司和买方已确定每个 CVR 的公允市场价值为 2025 年 9 月 24 日的 0.80 美元。
</div>As a result of the completion of the Arrangement, it is expected that the Shares will be de-listed from the Toronto Stock Exchange on or about September 26, 2025 and from the Nasdaq Capital Market on or about September25,2025. The Company shall apply to cease to be a reporting issuer under Canadian securities laws in all provinces of Canada. The Company will also deregister the Shares under the U.S. Securities Exchange Act of 1934, as amended.
<div class="lb-trans">由于安排的完成，预计股份将在 2025 年 9 月 26 日左右从多伦多证券交易所退市，并将在 2025 年 9 月 25 日左右从纳斯达克资本市场退市。公司将申请在加拿大所有省份停止作为报告发行人。公司还将根据《1934 年美国证券交易法》修订版注销股份。
</div>Early Warning Reporting
<div class="lb-trans">提前警告报告
</div>Immediately prior to the effective date of the Arrangement, the Purchaser and its affiliates did not own any Shares. An early warning report will be filed on SEDAR+ at www.sedarplus.ca under the Company's profile. Further information and/or a copy of the early warning report may be obtained from the contacts below. The Purchaser's head office is located at CB Biotechnology, LLC c/o Honigman LLP, 2290 First National Building, 660 Woodward Avenue, Detroit, MI 48226-3506.
<div class="lb-trans">在安排的生效日期之前，买方及其关联公司未持有任何股份。提前警告报告将在 www.sedarplus.ca 的公司档案下提交至 SEDAR+。有关更多信息和/或提前警告报告的副本，请联系以下人员。买方的总部位于 CB Biotechnology, LLC c/o Honigman LLP, 2290 First National Building, 660 Woodward Avenue, Detroit, MI 48226-3506。
</div>About Theratechnologies
<div class="lb-trans">关于 Theratechnologies
</div>Theratechnologies (TSX: TH) (NASDAQ: THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is available on its website at www.theratech.com.
<div class="lb-trans">Theratechnologies（TSX: TH）（NASDAQ: THTX）是一家专注于商业化创新疗法的专业生物制药公司，这些疗法有潜力重新定义护理标准。有关 Theratechnologies 的更多信息，请访问其网站 www.theratech.com。
</div>About Future Pak
<div class="lb-trans">关于 Future Pak
</div>Founded in 1977 and headquartered in Wixom, Michigan, Future Pak, along with its affiliates, is a privately held contract manufacturer, packager and distributor of pharmaceutical and nutraceutical products. Future Pak operates across retail, specialty and institutional markets, leveraging its robust infrastructure and partner network to deliver quality-first, patient-centric solutions.
<div class="lb-trans">Future Pak 成立于 1977 年，总部位于密歇根州 Wixom，连同其关联公司，是一家私营合同制造商、包装商和药品及营养保健品的分销商。Future Pak 在零售、专业和机构市场运营，利用其强大的基础设施和合作伙伴网络提供以质量为先、以患者为中心的解决方案。
</div>Forward-Looking Information
<div class="lb-trans">前瞻性信息
</div>This press release contains forward-looking statements and forward-looking information (collectively,“ Forward-Looking Statements”), within the meaning of applicable securities laws, that are based on our management’s beliefs and assumptions and on information currently available to our management. You can identify Forward-Looking Statements by terms such as “may”, “will”, “if”, “should”, “could”, “promising”, “would”, “outlook”, “believe”, “plan”, “envisage”, “anticipate”, “expect” and “estimate”, or the negatives of these terms, or variations of them. The Forward-Looking Statements contained in this press release include, but are not limited to, statements regarding the delisting of the Shares from the Toronto Stock Exchange and from the Nasdaq Capital Market, the Company ceasing to be a reporting issuer under Canadian securities laws in all provinces of Canada and the deregistration of the Shares under the U.S. Securities Exchange Act of 1934, as amended.
<div class="lb-trans">本新闻稿包含前瞻性声明和前瞻性信息（统称为 “ 前瞻性声明”），根据适用的证券法，这些声明基于我们管理层的信念和假设以及当前可用的信息。您可以通过 “可能”、“将”、“如果”、“应该”、“可以”、“有希望”、“会”、“展望”、“相信”、“计划”、“设想”、“预期”、“期待” 和 “估计” 等术语或这些术语的否定形式或变体来识别前瞻性声明。本新闻稿中包含的前瞻性声明包括但不限于关于股份从多伦多证券交易所和纳斯达克资本市场退市、公司在加拿大所有省份停止作为报告发行人的声明，以及根据修订版《1934 年美国证券交易法》注销股份的声明。
</div>These Forward-Looking Statements express, as of the date of this press release, the estimates, predictions, projections, expectations, or opinions of the Company about future events or results, as well as other assumptions, both general and specific, that the Company believes are appropriate in the circumstances. Although the Company believes that the expectations produced by these Forward-Looking Statements are founded on valid and reasonable bases and assumptions, these Forward-Looking Statements are inherently subject to important risks and uncertainties, many of which are beyond the Company’s control, such that actual results may differ significantly from those that are disclosed in or implied by such Forward-Looking Statements. The important risks and uncertainties include, but are not limited to, the possibility that the Shares will not be delisted from the Toronto Stock Exchange or the Nasdaq Capital Market within the timing currently contemplated, that the Shares may not be delisted at all, due to failure to satisfy, in a timely manner or otherwise, conditions necessary for the delisting of the Shares or for other reasons, that the Company’s application to cease to be a reporting issuer under applicable Canadian securities laws may not be accepted or may be delayed and that the Company may fail to achieve any milestones relating to the CVRs.
<div class="lb-trans">这些前瞻性声明表达了截至本新闻稿日期，公司对未来事件或结果的估计、预测、展望、期望或意见，以及公司认为在特定情况下适当的其他一般性和特定假设。尽管公司相信这些前瞻性声明所产生的期望是基于有效和合理的基础和假设，但这些前瞻性声明本质上受到重要风险和不确定性的影响，其中许多超出了公司的控制范围，因此实际结果可能与这些前瞻性声明中披露或暗示的结果有显著差异。重要的风险和不确定性包括但不限于，股票可能不会在当前预期的时间内从多伦多证券交易所或纳斯达克资本市场退市，股票可能根本不会退市，原因可能是未能及时或以其他方式满足退市所需的条件，或其他原因，公司申请根据适用的加拿大证券法停止作为报告发行人的申请可能不会被接受或可能会延迟，以及公司可能未能实现与 CVR 相关的任何里程碑。
</div>Readers are cautioned that the foregoing list of factors is not exhaustive and undue reliance should not be placed on Forward-Looking Statements. As a result, readers are advised that actual results may differ materially from expected results. Unless otherwise required by applicable securities laws, the Company expressly disclaims any intention, and assumes no obligation to update or revise any Forward-Looking Statements whether as a result of new information, future events or otherwise.
<div class="lb-trans">读者需注意，以上因素列表并不详尽，不应对前瞻性声明过度依赖。因此，建议读者实际结果可能与预期结果有实质性差异。除非适用的证券法另有要求，公司明确声明不打算，也不承担更新或修订任何前瞻性声明的义务，无论是由于新信息、未来事件还是其他原因。
</div>For further information, please contact:
<div class="lb-trans">如需更多信息，请联系：
</div>Future Pak
<div class="lb-trans">Future Pak
</div>Investors and media may contact media@futurepak.com.
<div class="lb-trans">投资者和媒体可联系 media@futurepak.com。
</div><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVek5UUTBNQ00zTVRZMU5UZzJJekl3T0RNek9ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTUzNTQ0MCM3MTY1NTg2IzIwODMzODM="/>
<img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/YjE5ZWExOGMtODBkOS00ZjgyLTg0MGUtZTU2MDBkOTNhMzM2LTEwOTQ5NTQtMjAyNS0wOS0yNS1lbg==/tiny/Theratechnologies.png" alt="" original-src="https://ml.globenewswire.com/media/YjE5ZWExOGMtODBkOS00ZjgyLTg0MGUtZTU2MDBkOTNhMzM2LTEwOTQ5NTQtMjAyNS0wOS0yNS1lbg==/tiny/Theratechnologies.png"/>

Theratechnologies 宣布完成被 Future Pak 收购 | THTX 股票新闻